Ads
related to: sellas life sciences stock forecast- Capital Ideas Podcast
Bringing You the Best Thinking
From Capital Group. Listen Now.
- Markets & Economy
View Our Latest Market Insights
and Get Economic Forecasts.
- Fixed Income Insights
View Our Latest Fixed Income
Investment Insights.
- Subscribe to Newsletter
Receive Our Latest Investment
Thinking In Your Inbox Each Week.
- Capital Ideas Podcast
Search results
Results From The WOW.Com Content Network
SELLAS Life Sciences Group ( NASDAQ:SLS ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.02m (flat on... SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per ...
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced topline data from its Phase 1/2 trial of galinpepimut-S (GPS) in WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian ...
Merger with Sellas Life Sciences. In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
For premium support please call: 800-290-4726 more ways to reach us
Liminal BioSciences' aim to develop best or first-in-class therapies targeting indications with significant unmet needs, where a novel small molecule approach may be better suited using its drug discovery platform, specialized know-how and data-driven development plans. Liminal BioSciences is a development stage biopharmaceutical company ...
Revenue. $1.3 billion (2020) [1] Number of employees. 3,700 (2020) [1] Website. integralife .com. Integra LifeSciences is a global medical device manufacturing company headquartered in Princeton, New Jersey. [3] [4] Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. [3]
Ads
related to: sellas life sciences stock forecast